Incyte Genomics Inc - INCY STOCK NEWS

Incyte (Nasdaq: INCY) has announced its upcoming participation at Citi's 2024 Global Healthcare Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 3:15 p.m. in Miami. Investors and interested parties can access the live webcast through Investor.Incyte.com, and a replay will remain available for 30 days following the presentation.

Incyte (Nasdaq:INCY) announced the granting of restricted stock unit awards (RSUs) and stock options to 27 new employees. The awards include 33,003 RSU shares and options to purchase 15,812 shares at $76.13 per share. The grants were made under the 2024 Inducement Stock Incentive Plan, effective November 1, 2024. RSUs vest 25% annually over four years, while stock options vest 25% after one year, with remaining portions vesting monthly over 36 months. Both are subject to continued employment.

Incyte (INCY) has announced its participation in two major healthcare investor conferences in November 2024. The company will present at the Guggenheim's Inaugural Healthcare Innovation Conference on November 11 at 2:00 pm EST and the Jefferies London Healthcare Conference on November 19 at 9:30 am GMT. Both presentations will be available via live webcast on Investor.Incyte.com and will remain accessible for replay for 30 days.

Incyte (INCY) reported strong Q3 2024 financial results with total revenues of $1,138 million, up 24% year-over-year. Jakafi net product revenues reached $741 million (+16% Y/Y), leading to raised full-year guidance of $2,740-$2,770 million. Opzelura cream revenues grew 52% to $139 million. The FDA approved Niktimvo for chronic graft-versus-host disease. The company filed an sNDA for ruxolitinib cream in pediatric atopic dermatitis and presented positive data for multiple pipeline candidates including CDK2 inhibitor, retifanlimab and tafasitamab.

Incyte has been named among the top five biotech and pharma employers by Science magazine for the seventh consecutive year, ranking third in 2024. The company was specifically recognized for its commitment to employee respect, social responsibility, and employee loyalty.

Additionally, Incyte received recognition from Newsweek as one of America's 100 Most Loved Workplaces and Most Loved Global Workplaces. These accolades highlight the company's dedication to fostering innovation, growth, and passion within its workforce. The complete Science magazine Top Employers survey and rankings will be featured in the October 25, 2024 print issue.

Incyte (Nasdaq:INCY) has expanded its Moments of Clarity program, an educational initiative highlighting stories of people living with mild to moderate atopic dermatitis (AD). The program now features additional patient perspectives, including Dr. Sandra Lee (known as Dr. Pimple Popper) and Emily, a mom of three. They share their experiences with AD and finding relief with Opzelura® (ruxolitinib) cream 1.5%.

Opzelura is a nonsteroidal, twice-daily cream for short-term and non-continuous treatment of mild to moderate eczema in certain people 12 and older. In a pivotal clinical trial, 54% of patients had clear to almost clear skin at 8 weeks, and 52% had a significant reduction in itch. The program aims to empower others to seek appropriate treatment and raise awareness about AD, which affects over 21 million people aged 12 and older in the U.S.

Incyte (Nasdaq:INCY) has announced the schedule for its third quarter financial results conference call and webcast. The event is set for October 29, 2024, with the following timeline:

• Q3 2024 Press Release: 7:00 a.m. ET
• Q3 2024 Conference Call: 8:00 a.m. ET

Participants can join via phone using the provided domestic and international dial-in numbers, or access the live webcast with slides at Investor.Incyte.com. A replay of the call will be available for thirty days, and the webcast will be accessible for ninety days.

Incyte (Nasdaq:INCY) has announced the granting of restricted stock unit awards (RSUs) to 26 new employees, representing a total of 22,107 shares of the company's common stock. These awards were made under Incyte's 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of October 1, 2024. The grants were approved by the compensation committee of Incyte's board of directors as an inducement for new employees joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the vesting commencement date, contingent on the employee's continued service with Incyte.

Incyte (Nasdaq:INCY) has announced an equity inducement award granted to Lee Heeson, the company's new Executive Vice President, Incyte International. The award, approved by the compensation committee of Incyte's Board of Directors, is in accordance with Nasdaq Listing Rule 5635(c)(4).

Mr. Heeson received 26,447 restricted stock units (RSUs) with a grant and vesting commencement date of October 1, 2024. The RSUs will vest in four equal installments of 25% each on the first four anniversaries of the vesting commencement date, contingent upon Mr. Heeson's continued service with Incyte on each vesting date.